| Literature DB >> 29675996 |
Sylvia I Pavlova1, Reid V Wilkening2, Michael J Federle3, Yu Lu4, Joel Schwartz4, Lin Tao1.
Abstract
Both cervical and throat cancers are associated with human papillomavirus (HPV). HPV infection requires cleavage of the minor capsid protein L2 by furin. While furin is present in the vaginal epithelium, it is absent in oral epithelial basal cells where HPV infection occurs. The objective of this study was to investigate whether common oral bacteria express furin-like peptidases. By screening strains representing 12 oral Streptococcus and Enterococcus species, we identified that eight Streptococcus strains displayed high levels of furin-like peptidase activity, with S. gordonii V2016 the highest. We constructed null mutations for 14 genes encoding putative endopeptidases in S. gordonii V2016. Results showed that three endopeptidases, PepO, PulO, and SepM, had furin-like activities. All three mutants showed decreased natural transformation by chromosomal DNA, while the pepO mutant also showed reduced transformation by plasmid DNA, indicating involvement of these endopeptidases in competence development. The purified S. gordonii PepO protein promoted infection of epithelial 293TT cells in vitro by HPV16 pseudovirus. In conclusion, oral bacteria might promote HPV infection and contribute to HPV tissue tropism and subsequent carcinogenesis in the oral cavity and throat by providing furin-like endopeptidases.Entities:
Keywords: HPV; Streptococcus; cancer; furin; peptidase; transformation
Mesh:
Substances:
Year: 2018 PMID: 29675996 PMCID: PMC6341032 DOI: 10.1002/mbo3.628
Source DB: PubMed Journal: Microbiologyopen ISSN: 2045-8827 Impact factor: 3.139
Bacterial strains and plasmids used in this study
| Strain/Plasmid | Characteristics | Reference |
|---|---|---|
|
| Wild‐type isolate | This study |
|
| Wild‐type isolate | Pavlova et al. ( |
|
| Wild‐type isolate | This study |
|
| Wild‐type isolate | This study |
|
| Wild‐type isolate | This study |
|
| Wild‐type isolate | This study |
|
| Wild‐type isolate | This study |
|
| CP1250; | Weng, Piotrowski, & Morrison ( |
|
| Wild‐type isolate | Simon & Ferretti ( |
|
| Wild‐type isolate | This study |
|
| Wild‐type isolate | This study |
|
| ATCC BAA‐1455 | Todd Kitten |
|
| Wild‐type isolate | This study |
|
| Wild‐type isolate | This study |
|
| Wild‐type isolates | This study |
|
| Wild‐type isolates | This study |
|
| Wild‐type isolates | This study |
|
| Wild‐type isolate | This study |
|
| Wild‐type isolate | This study |
|
| Wild‐type isolates | This study |
|
| Wild‐type isolates | This study |
|
| ||
|
| Deletion of SGO_0316 & SGO_0317 with KmR | This study |
|
| Deletion of SGO_0566 with KmR | This study |
|
| Deletion of SGO_0974 with KmR | This study |
|
| Deletion of SGO_2150 with KmR | This study |
|
| Inactivation of SGO_0221 with pSF151, KmR | This study |
|
| Inactivation of SGO_0237 with pSF151, KmR | This study |
|
| Inactivation of SGO_0408 with pSF151, KmR | This study |
|
| Inactivation of SGO_0652 with pSF151, KmR | This study |
|
| Inactivation of SGO_0664 with pSF151, KmR | This study |
|
| Inactivation of SGO_0796 with pSF151, KmR | This study |
|
| Inactivation of SGO_0847 with pSF151, KmR | This study |
|
| Inactivation of SGO_1298 with pSF151, KmR | This study |
|
| Inactivation of SGO_1799 with pSF151, KmR | This study |
|
| Inactivation of SGO_2009 with pSF151, KmR | This study |
|
| Inactivations with pVA891 and pSF151, EmR, KmR, | This study |
|
| Inactivations with pVA891, pSF152 and pSF151, EmR, SpR, KmR | This study |
|
| ||
|
| Transformed with the | This study |
|
| Transformed with the | This study |
|
| Cloning strain | Yanisch‐Perron, Vieira, & Messing, ( |
|
| Cloning strain | Hanahan ( |
|
| Protein overexpression strain | New England BioLabs |
| Plasmid | ||
| pSF151 | Streptococcal integration plasmid, 3.5 kb, KmR | Tao ( |
| pSF152 | Streptococcal integration plasmid, 3.2 kb, SpR | Tao ( |
| pVA891 | Streptococcal integration plasmid, 5.9 kb, EmR | Tao ( |
| pA13 | Lactic acid bacteria‐ | Kojic et al. ( |
| pET21a | Cloning/expression, 5.4 kb, AmpR | Novagen |
| pET21a‐ | pET21a containing | This study |
Oligonucleotides used in this study
| Oligonucleotide (5′→3′) | Sequence | Restriction enzyme |
|---|---|---|
| Construction of | ||
| SubA‐F1 | ataaggttaactcccttcgacaagctggtg | |
| SubA‐R1 | tgatttccc |
|
| SubB‐F2 | ggttctaca |
|
| SubB‐R2 | actgaccaaatgctggttactcttagcatc | |
| Construction of | ||
| Sgc‐F1 | cgtaggatcccttcgtgaccaaggat | |
| Sgc‐R1 | tcga |
|
| Sgc‐F2 | caggac |
|
| Sgc‐R2 | gccttagcttgtgcataggcctctaag | |
| Construction of | ||
| secA2‐F1 | ttgccagaagcctatgctg | |
| secA2‐R1 | gcta |
|
| secA2‐F2 | atgc |
|
| secA2‐R2 | ttaagaatagccaggcgctgg | |
| Construction of | ||
| SepA‐F1 | gcgaccgttcgcttagaaggcgaatgctct | |
| SepA‐R1 | gcta |
|
| SepA‐F2 | gaccagcattag |
|
| SepA‐R2 | ttagagagactaatctttacttcgactccc | |
| Construction of SGO_0221 mutant | ||
| Sgo‐221F | ctgag |
|
| Sgo‐221R | gagcc |
|
| Construction of SGO_0237 mutant | ||
| Sgo‐237F | ttggga |
|
| Sgo‐237R | gcat |
|
| Construction of SGO_0408 mutant | ||
| Sgo‐408F | gcagctgt |
|
| Sgo‐408R | cagctgaccttt |
|
| Construction of SGO_0652 mutant | ||
| Sgo‐652F | gactggtg |
|
| Sgo‐652R | cgtaaggttg |
|
| Construction of SGO_0664 mutant | ||
| Sgo‐664F | gaatgag |
|
| Sgo‐664R | cacttggtac |
|
| Construction of SGO_0796 mutant | ||
| Sgo‐796F | ttta |
|
| Sgo‐796R | gaaagaac |
|
| Construction of SGO_0847 mutant | ||
| Sgo‐847F | ggaatgga |
|
| Sgo‐847R | ttggc |
|
| Construction of SGO_1298 mutant | ||
| Sgo‐1298F | gacttccca |
|
| Sgo‐1298R | gctcgttct |
|
| Construction of SGO_1799 mutant | ||
| Sgo‐1799F | gtgaa |
|
| Sgo‐1799R | gcggctatc |
|
| Construction of SGO_2009 mutant | ||
| Sgo‐2009F | gaagggg |
|
| Sgo‐2009R | cact |
|
| Cloning | ||
| RW112 | tttaagaaggagatatacatatgACACGACTGCAAGATGATTTTTATG | |
| RW113 | cagtggtggtggtggtggtgctcgagCCAAATAATCACACGATCTCC | |
| plasmid flanking region in lower case | ||
Figure 1(a) Furin‐like activity of strains representing 12 oral and throat Streptococcus and Enterococcus species. (b) Furin‐like activities of S. gordonii V2016 and its 13 peptidase and the secA2 mutants (one measure per sample). (c) Furin‐like activities of S. gordonii and its furin‐like peptidase‐negative mutants. **Statistically very significant difference (p < .01) between different groups: the wild‐type, single, double and triple mutants, and the buffer control. Each bar represents the mean of triplicate values ± standard deviation
Figure 2(a) Affinity purification of recombinant S. gordonii PepO from E. coli shown in SDS–PAGE. 1) Pellet without IPTG; 2) Pellet with IPTG for 6 hr; 3) Crude lysate; 4) Elution fraction 2 (flow through); 5) Fraction 8; 6) Fraction 9; and 7) Fraction 10. Arrow: rPepO. (b) rPepO activation by bacteria (E. coli JM109, S. salivarius 101‐1, S. pyogenes NS05‐24, and S. gordonii pepO mutant) and mammalian cells (A549, SCC9 and 293TT). Buffer controls are buffer with indicated cells. 293TT cells released about 19,000 RFU fluorescence from the furin substrate with or without added rPepO and furin, showing high endogenous furin level. (c) rPepO activation by bacterial peptidoglycan (PG). Sp. S. pyogenes; Bs, B. subtilis. Buffer controls are buffer with indicated PG. Note: B. subtilis PG in buffer displayed high furin‐like protease activity, indicating that these PGs may contain proteases. (d) rPepO activation by chymotrypsin, trypsin, papain, pepsin, and proteinase K. Pronase (protease from Streptomyces griseus) (Calbiochem) released 12,000 RFU fluorescence from the furin substrate with or without added rPepO (one measure per sample). Buffer controls are buffer with indicated protease. (e) rPepO activation by chymotrypsin. Both buffer control and rPepO samples contain chymotrypsin with indicated amount in the figure. *Significant difference (p < .05); **very significant difference (p < .01) compared with controls
Figure 3Transformation of S. gordonii V2016 and its pepO‐defective mutant. (a) Competence development as function of time. (b) Transformation rates between plasmid and chromosomal DNAs. Comparing with the wild type, the pepO mutant shows significant decrease in both plasmid and chromosomal DNA transformations. **Very significant difference (p < .01) when compared with the control
Figure 4HPV16 PsV infection of 293TT cells boosted by S. gordonii rPepO. (A) HPV16 PsV infection on day 6 detected by fluorometer. a, HPV16 PsV. b, HPV‐16 PsV + CMK. c, HPV‐16 PsV + CMK + furin (2 Units, left; 10 Units, right). d, HPV‐16 PsV + CMK + S. gordonii rPepO (14 μg, left; 56 μg, right). **Very significant difference (p < .01) when compared with the control (b). (B) HPV16 PsV infection on day 3 detected by fluorescent microscope. Bar: 200 μm. a, HPV16 PsV infection of 293TT. B, HPV‐16 PsV infection of 293TT inhibited by CMK. c, HPV‐16 PsV infection of 293TT with CMK promoted with 10 units of furin. d, HPV‐16 PsV infection of 293TT with CMK promoted with 56 μg of rPepO